Meeting Banner
Abstract #3894

Improved the performance of differential diagnosis between Prostate Cancer and Benign Prostate Hyperplasia using APT and mDIXON-Quant

Xue Ren1, Ailian Liu1, Lihua Chen1, Shuang Li1, Yue Wang1, Jiazheng Wang2, Qingwei Song1, Sun Peng2, Renwang Pu3, and Yuanfei Li1
1The First Affiliated Hospital of Dalian Medical University, Dalian, China, 2Philips Healthcare, Beijing, China, 3First Affiliated Hospital of Dalian Medical University, Dalian, China

Accurate identifying prostate cancer (PC) from benign prostatic hyperplasia (BPH) is of great significance for timely and proper treatment. Amide proton transfer (APT) is a novel MRI method sensitive to several kinds of cancers. mDIXON-Quant is a powerful quantitive technique for simultaneous fat quantification and R2* mapping, which can reflect the tissue contents and properties. This study aims to assess the diagnostic performance of APT and mDIXON-Quant on differentiating prostate cancers and benign prostate hyperplasia. Results indicate that the combination of APT and mDIXON-Quant can enhance the differential diagnosis of PC and BPH.

This abstract and the presentation materials are available to members only; a login is required.

Join Here